Patents by Inventor Monica BINASCHI

Monica BINASCHI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-LY75 ANTIBODY
    Publication number: 20220289851
    Abstract: The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) a second anti-cancer entity; nucleic acids encoding antibody combinations; methods for preparing antibody combinations; and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity.
    Type: Application
    Filed: May 3, 2022
    Publication date: September 15, 2022
    Applicant: BERLIN-CHEMIE AG
    Inventors: Monica BINASCHI, Mario BIGIONI, Giuseppe MERLINO, Cecilia SIMONELLI, Francesco BERTONI, Andrea PELLACANI
  • Pharmaceutical combinations comprising an anti-LY75 antibody
    Patent number: 11365258
    Abstract: The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) a second anti-cancer entity; nucleic acids encoding antibody combinations; methods for preparing antibody combinations; and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: June 21, 2022
    Assignee: BERLIN-CHEMIE AG
    Inventors: Monica Binaschi, Mario Bigioni, Giuseppe Merlino, Cecilia Simonelli, Francesco Bertoni, Andrea Pellacani
  • PHARMACEUTICAL COMBINATIONS
    Publication number: 20210113690
    Abstract: The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) Venetoclax; methods for preparing pharmaceutical combinations; and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity.
    Type: Application
    Filed: June 13, 2019
    Publication date: April 22, 2021
    Applicant: BERLIN-CHEMIE AG
    Inventors: Giuseppe MERLINO, Mario BIGIONI, Monica BINASCHI, Andrea PELLACANI
  • ANTIBODIES AGAINST BST1 FOR PREVENTING OR TREATING MYELODYSPLASTIC SYNDROME
    Publication number: 20210032360
    Abstract: The present disclosure relates to methods of preventing or treating myelodysplastic syndrome (MDS) using antibodies or antigen-binding portions thereof directed against BST1.
    Type: Application
    Filed: April 12, 2019
    Publication date: February 4, 2021
    Applicant: BERLIN-CHEMIE AG
    Inventors: Daniela BELLAROSA, Corrado CARRISI, Andrea PELLACANI, Chirstian ROHLFF, James Edward ACKROYD, Monica BINASCHI
  • PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-BST-1 ANTIBODY AND A CYTIDINE ANALOGUE
    Publication number: 20200231694
    Abstract: The disclosure relates to pharmaceutical combinations comprising antibodies against BST1 (ADP-ribosyl cyclase 2) together with a cytidine analogue or a pharmaceutically-acceptable salt thereof, and methods for the treatment of diseases, such as cancers mediated by BST1 (ADP-ribosyl cyclase 2) expression/activity and/or associated with abnormal expression/activity of BST1.
    Type: Application
    Filed: July 20, 2018
    Publication date: July 23, 2020
    Applicant: BERLIN-CHEMIE AG
    Inventors: Cecilia SIMONELLI, Andrea PELLACANI, Monica BINASCHI, Daniela BELLAROSA, Corrado CARRISI
  • PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-LY75 ANTIBODY
    Publication number: 20200040086
    Abstract: The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) a second anti-cancer entity; nucleic acids encoding antibody combinations; methods for preparing antibody combinations; and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity.
    Type: Application
    Filed: September 3, 2018
    Publication date: February 6, 2020
    Applicant: BERLIN-CHEMIE AG
    Inventors: Monica BINASCHI, Mario BIGIONI, Giuseppe MERLINO, Cecilla SIMONELLI, Francesco BERTONI